BRAIN CANCER

A new FDA-approved trial explores innovative treatments for recurrent glioblastoma, offering hope for patients facing this aggressive brain cancer.

FDA accelerates approval of dordaviprone, the first targeted therapy for aggressive diffuse midline glioma, offering hope for patients with H3 K27M mutation.

Hemispherian's GLIX1 gains FDA approval for glioblastoma trials, promising a novel therapy targeting DNA repair in tumor cells.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.

Researchers explore glioblastoma's genetic complexity using innovative spatial profiling, aiming to enhance treatment strategies and understand tumor resistance.

A study strongly supports stereotactic radiation for up to 20 brain metastases, proving superior to even advanced whole-brain techniques and widely accessible.

The FDA designates SH-110 as an orphan drug, offering a safer oral treatment option for glioma patients with swallowing difficulties.

Ayal Aizer, MD, MHS, discusses the findings of a phase 3 study investigating the use of stereotactic radiation vs whole-brain radiation in patients with 5 to 20 brain metastases.

FDA designates MB-101 CAR T-cell therapy for glioblastoma, highlighting its potential in treating aggressive brain tumors with innovative combination strategies.

A new trial optimizes rhenium Re 186 obisbemeda dosing for treating leptomeningeal metastases, aiming to enhance safety and efficacy in CNS cancer therapy.

The SonoClear System revolutionizes neurosurgery with FDA breakthrough designation, enhancing ultrasound imaging for safer tumor resections in glioma surgeries.

Myrio's PHOX2B PC-CAR T therapy gains FDA approval for human trials, promising innovative treatment for patients with high-risk neuroblastoma.

Ayal Aizer, MD, MHS, discusses the unmet needs in treating patients with brain metastases.

Manmeet Ahluwalia, MD, MBA, FASCO, shares a message during Brain Cancer Awareness Month.

BCB-276 has earned regenerative medicine advanced therapy designation from the FDA in diffuse intrinsic pontine glioma, an incurable pediatric tumor.

The anti-GD2 therapy naxitamab has been included in the NCCN Clinical Practice Guidelines in Oncology for the treatment of patients with neuroblastoma.

The FDA requires more data to approve the application of TLX101-CDx for the detection and differentiation of glioma.

FDA designates BCB-276 as a breakthrough therapy for pediatric DIPG, offering hope for improved treatment of this challenging brain tumor.

Preliminary results from the phase 2 IPAX-Linz study show encouraging efficacy and a favorable safety profile for TLX101 in recurrent high-grade glioma.

A pilot study will evaluate Alpha DaRT for the treatment of patients with recurrent glioblastoma.

Early results show that the combination of VXM01 plus avelumab demonstrated tolerable safety in recurrent glioblastoma.

A study found that sonodynamic therapy showed no adverse events and demonstrated cancer cell death in 3 patients with glioblastoma.

The FDA has granted a priority review to dordaviprone for treating patients with recurrent H3K27M-mutant diffuse glioma, a population with limited treatment options.

The FDA approved mirdametinib for the treatment of adult and pediatric patients with neurofibromatosis type 1-associated plexiform neurofibromas.

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for relapsed/refractory pediatric low-grade glioma with BRAF mutations or rearrangements.